Citi tells investors it’s time to sell Moderna after 600%-plus stock gains
Published . Updated .
Revenue and profit forecasts fail to justify the hype baked into Moderna’s share price, according to Citi’s analysts.
Directly affected
- MRNA Moderna
Named in this report.
Indirectly affected
- BAMG BROOKSTONE GROWTH STOCK ETF
GA selected BAMG as a RELATED security because its canonical security name directly matches this event's themes: stock. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- GDE WISDOMTREE EFFICIENT GOLD PLUS EQUITY STRATEGY FUND
GA selected GDE as a RELATED security because its canonical security name directly matches this event's themes: plus. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- LTH LIFE TIME GROUP HOLDINGS INC COMMON STOCK
GA selected LTH as a RELATED security because its canonical security name directly matches this event's themes: stock, time. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- BAMV BROOKSTONE VALUE STOCK ETF
GA selected BAMV as a RELATED security because its canonical security name directly matches this event's themes: stock. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- EMPB EFFICIENT MARKET PORTFOLIO PLUS ETF TRUST UNITS
GA selected EMPB as a RELATED security because its canonical security name directly matches this event's themes: plus. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- FIXT TCW CORE PLUS BOND ETF
GA selected FIXT as a RELATED security because its canonical security name directly matches this event's themes: plus. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
Revenue and profit forecasts fail to justify the hype baked into Moderna’s share price, according to Citi’s analysts.
Source: MarketWatch
The price since 30 Sep 2026: Moderna (MRNA) versus the S&P 500
Since the first closing price after “Citi tells investors it’s time to sell Moderna after 600%-plus stock gains,” Moderna (MRNA) is +20.08%. The S&P 500 fund (SPY) is +0.33% over the same days, a +19.76% difference versus the market.
Who reported a Moderna (MRNA) trade near this story
- Maria Elvira Salazar sell Moderna (MRNA) ($1,001 - $15,000). That is 6 days before publication, inside 30 days. The filing is listed beside the story “Citi tells investors it’s time to sell Moderna after 600%-plus stock gains.”
- Rohit Khanna buy Moderna (MRNA) ($1,001 - $15,000). That is 26 days before publication, inside 30 days. The filing is listed beside the story “Citi tells investors it’s time to sell Moderna after 600%-plus stock gains.”
- Donald J Trump buy Moderna (MRNA) ($1,001 - $15,000). That is 33 days before publication, inside 60 days. The filing is listed beside the story “Citi tells investors it’s time to sell Moderna after 600%-plus stock gains.”
- April McClain Delaney sell Life Time Group Holdings (LTH) ($100,001 - $250,000). That is 36 days before publication, inside 60 days. The filing is listed beside the story “Citi tells investors it’s time to sell Moderna after 600%-plus stock gains.”
- April McClain Delaney buy Life Time Group Holdings (LTH) ($1,001 - $15,000). That is 37 days before publication, inside 60 days. The filing is listed beside the story “Citi tells investors it’s time to sell Moderna after 600%-plus stock gains.”
- Maria Elvira Salazar sell Moderna (MRNA) ($1,001 - $15,000). That is 42 days before publication, inside 60 days. The filing is listed beside the story “Citi tells investors it’s time to sell Moderna after 600%-plus stock gains.”
- Maria Elvira Salazar buy Moderna (MRNA) ($1,001 - $15,000). That is 42 days before publication, inside 60 days. The filing is listed beside the story “Citi tells investors it’s time to sell Moderna after 600%-plus stock gains.”
- April McClain Delaney buy Life Time Group Holdings (LTH) ($1,001 - $15,000). That is 54 days before publication, inside 60 days. The filing is listed beside the story “Citi tells investors it’s time to sell Moderna after 600%-plus stock gains.”
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Moderna (MRNA)
Companies carried with this story
- MRNA Moderna
For “Citi tells investors it’s time to sell Moderna after 600%-plus stock gains,” Moderna (MRNA) is linked, with no stored direction, high confidence. Reason on file: The reported development directly names MODERNA INC in the headline; GA resolved that company to MRNA
- BAMG Brookstone Growth Stock Etf
In “Citi tells investors it’s time to sell Moderna after 600%-plus stock gains,” Brookstone Growth Stock Etf (BAMG) is linked, with no stored direction, medium confidence. Reason on file: GA selected BAMG as a RELATED security because its canonical security name directly matches this event's themes: stock. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- GDE Wisdomtree Efficient Gold Plus Equity Strategy Fund
Wisdomtree Efficient Gold Plus Equity Strategy Fund (GDE) is linked, with no stored direction, medium confidence in the 30 Sep 2026 story “Citi tells investors it’s time to sell Moderna after 600%-plus stock gains.” Reason on file: GA selected GDE as a RELATED security because its canonical security name directly matches this event's themes: plus. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- LTH Life Time Group Holdings
In “Citi tells investors it’s time to sell Moderna after 600%-plus stock gains,” Life Time Group Holdings (LTH) is linked, with no stored direction, medium confidence. Reason on file: GA selected LTH as a RELATED security because its canonical security name directly matches this event's themes: stock, time. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- BAMV Brookstone Value Stock Etf
Brookstone Value Stock Etf (BAMV) is linked, with no stored direction, medium confidence in the 30 Sep 2026 story “Citi tells investors it’s time to sell Moderna after 600%-plus stock gains.” Reason on file: GA selected BAMV as a RELATED security because its canonical security name directly matches this event's themes: stock. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- EMPB Efficient Market Portfolio Plus Etf Trust Units
For “Citi tells investors it’s time to sell Moderna after 600%-plus stock gains,” Efficient Market Portfolio Plus Etf Trust Units (EMPB) is linked, with no stored direction, medium confidence. Reason on file: GA selected EMPB as a RELATED security because its canonical security name directly matches this event's themes: plus. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- FIXT Tcw Core Plus Bond Etf
For “Citi tells investors it’s time to sell Moderna after 600%-plus stock gains,” Tcw Core Plus Bond Etf (FIXT) is linked, with no stored direction, medium confidence. Reason on file: GA selected FIXT as a RELATED security because its canonical security name directly matches this event's themes: plus. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Moderna (MRNA)
Moderna (MRNA) is the company in “Citi tells investors it’s time to sell Moderna after 600%-plus stock gains,” the 30 Sep 2026 this story story.
What ties Moderna (MRNA) to the headline is this: The reported development directly names MODERNA INC in the headline; GA resolved that company to MRNA
A second company, Brookstone Growth Stock Etf (BAMG), is listed for a different reason: GA selected BAMG as a RELATED security because its canonical security name directly matches this event's themes: stock. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
The price range for Moderna (MRNA), and the dates in the story
BAMG traded between 43.54 and 45.76 across 11 sessions. The latest close on file is 45.02. GDE traded between 62.95 and 67.64 across 20 sessions. The latest close on file is 63.66. MRNA traded between 168.05 and 242.18 across 20 sessions. The latest close on file is 226.88.
A simple score for Moderna (MRNA)
46 out of 100
“Citi tells investors it’s time to sell Moderna after 600%-plus stock gains” scores 46 out of 100. The score uses 1 sources, and 7 linked companies.